Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (336)	4/15/2002 12:14:35 PM
From: Jibacoa	Read Replies (1) of 544

ADLR Had a GOOD up-gap after the news of their deal with GSK.L for the rights on alvimopan which is on Phase III for post-surgical adynamic ileus and opioids related constipation.<g> siliconinvestor.com siliconinvestor.com ADLR is to receive $50 million "signing fee" and up to $220 million in "milestone payments".<g> ADLR seems to have made a good double bottom with Friday's L and the September 2001 L.<g> siliconinvestor.com The insiders hold 57% and had done some selling lately, but the institutions which reportedly hold 55% (128% of the float) had been buying more.<g> ADLR reportedly has $5.03 cash/share and although they loss was $49 M (EBITDA) in the last 12 months, that is the amount they are going to receive as a "signing fee".<g> Today's volume is going to be more than 10x its daily average and they have a Current Ratio of 14.65 ($156M in cash.<g>)and a short interest of 1.4 M (about 10% of the float or 10x the recent daily average.<g) With today's news the shares of ADLR , IMHO, look very interesting.<g> The next resistance is the February 14 H at 15.10.<g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next